As of 30 Sep 2026
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 11.48% | ₹788.06 Cr | 43,38,091 |
| Dr. Reddy's Laboratories Ltd. | 9.73% | ₹667.57 Cr | 54,14,201 |
| Cipla Ltd. | 5.79% | ₹396.98 Cr | 29,49,351 |
| Biocon Ltd. | 5.33% | ₹365.74 Cr | 98,76,830 |
| Mankind Pharma Ltd. | 5.04% | ₹346.05 Cr | 13,82,093 |
| Alkem Laboratories Ltd. | 4.81% | ₹330.36 Cr | 6,39,791 |
| Medplus Health Services Ltd. | 4.31% | ₹295.65 Cr | 45,14,490 |
| Cohance Lifesciences Ltd. | 4.05% | ₹278.24 Cr | 62,66,692 |
| Divi's Laboratories Ltd. | 3.78% | ₹259.25 Cr | 2,79,019 |
| Syngene International Ltd. | 3.50% | ₹240.3 Cr | 65,78,033 |
The fund is rated 4 stars. The strongest areas were investment selection within each asset type and investment selection within each industry, while balance between returns and downside risk provided some support. Higher annual fee of 2.06% and above-average fund size of Rs 6,861.2 crore were minor drawbacks.
This fund has a good track record with Asset Selection/Timing, a good track record with Stock Selection/Timing. It is important to note, however, that this fund has a 6861.203 AUM and a 2.06 expense ratio. Considering all these factors, we have rated this fund as 4.0 star.
Our score weighs long-term performance, risk and consistency — not just past returns.
As of 5 Nov 2026
As of 31 Oct 2026
Long term wealth creation. An Equity Scheme that predominantly invests in Equity and Equity related securities of companies in Healthcare Sector.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Exit load of 1% if redeemed within 15 days.
Mutual funds are subject to market risk. Read all scheme documents carefully.
